Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT
Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Jun 30, 2023
Trial Information
Current as of September 05, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how wearable health technology (WHT), like fitness trackers, can be used to help doctors and patients better understand changes in health while receiving cancer treatment. The study aims to see if using this technology in a busy radiation oncology clinic can help identify any physical declines in patients who are undergoing both radiation therapy and other treatments at the same time. Participants will wear a device that tracks important health information such as heart rate and daily steps during their treatment and for four weeks afterward. They will then upload this data to the clinic for review.
To join the study, participants must be at least 18 years old, speak English, and be receiving treatment for cancer at Novant-New Hanover Regional Medical Center. They should also be able to understand the study procedures and provide consent to participate. It’s important to note that individuals with conditions affecting their ability to understand or give consent, like dementia or severe mental health issues, will not be eligible. Overall, this study could provide valuable insights into how tracking health data can improve care for cancer patients.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
- • Subjects
- • 1. All genders aged ≥ 18 years of age.
- • 2. English-speakers
- • 3. Able to understand and cooperate with study procedures.
- • 4. Signed and dated informed consent.
- • 5. Subjects being seen at Novant-New Hanover Regional Medical Center for diagnosis and management of cancer.
- • 6. Subjects prescribed to receive concurrent radiation therapy and systemic therapy either definitively or postoperatively.
- • 7. Signed and dated HIPAA authorization for the release of personal health information.
- • Providers
- • 1. All genders aged ≥ 18 years of age.
- • 2. English speakers.
- • 3. Able to understand and cooperate with study procedures.
- • 4. Signed and dated informed consent.
- • Exclusion Criteria Both Subjects and care providers
- • 1. Has dementia, altered mental status, or any psychiatric or co-morbid condition prohibiting the understanding or rending of informed consent
About Unc Lineberger Comprehensive Cancer Center
The UNC Lineberger Comprehensive Cancer Center is a leading research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials and comprehensive patient care. As a National Cancer Institute-designated comprehensive cancer center, it integrates cutting-edge research, interdisciplinary collaboration, and patient-centered approaches to address diverse oncology challenges. With a commitment to translating scientific discoveries into effective therapies, UNC Lineberger strives to improve outcomes for patients while fostering a robust environment for education and training in cancer research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wilmington, North Carolina, United States
Patients applied
Trial Officials
Lukasz Mazur, MD
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported